1. Here is the core of Value Line’s advice: the rank for Performance,™ the technical rank; the rank for Safety;™ Beta—the stock’s sensitivity to fluctuations of the market as a whole.


3. Statistical milestones that reveal significant long-term trends. The statistics are presented in two ways: 1) the upper series records results on a per-share basis; 2) the lower records results on a company basis.

4. **Footnote A** - This footnote will identify the number of analysts who have recently increased or decreased their earnings estimates for the company. This footnote will also identify the consensus 5-year earnings growth estimate, which is expressed on an average annual percentage basis.

5. **Footnote B** - This footnote identifies how many analysts contributed to this year’s (2008) annual earnings estimate, which is printed in the annual column labeled 2008. If no analyst identified a 2008 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

6. **Footnote C** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

7. **Footnote D** - This footnote will identify the number of analysts who have recently increased or decreased their earnings estimates for the company. This footnote will also identify the consensus 5-year earnings growth estimate, which is expressed on an average annual percentage basis.

8. **Footnote E** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

9. **Footnote F** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

10. **Footnote G** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

11. **Footnote H** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

12. **Footnote I** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

13. **Footnote J** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

14. **Footnote K** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

15. **Footnote L** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

16. **Footnote M** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

17. **Footnote N** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

18. **Footnote O** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

19. **Footnote P** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

20. **Footnote Q** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

21. **Footnote R** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

22. **Footnote S** - This footnote identifies how many analysts contributed to the following year’s (2009) annual earnings estimate, which is printed on the left side of the annual column labeled 2009/2010. If no analyst contributed to a 2009 or 20010 annual estimate, this footnote is eliminated and N/A is printed in the annual column.

---

13. The number of shares traded monthly.

14. Monthly price ranges of the stock—plotted on a ratio (logarithmic) grid to show percentage changes in true proportion. For example, a ratio chart equalizes the move of a $10 stock that rises to $11 with that of a $100 stock that rises to $110. Both have advanced 10% and move the same distance on a ratio grid.

15. Relative price strength, the dotted line, describes the stock’s price performance relative to the Value Line Arithmetic Average of 1700 stocks.

16. Dividend yield—current annualized cash dividends divided by the recent price.

17. Twelve month moving average—shows average stock price over the entire prior twelve months.

18. Relative P/E ratio—the stock’s current trailing P/E divided by the median P/E for all 3500 stocks under review.

19. Trailing P/E ratio—the most recent price divided by the past 12 months earnings.

20. Recent price—nine days prior to date appearing on each report.

21. The stock’s highest and lowest prices of the year.

22. Legends/stock split table.
### Value Line Small and Mid-Cap Sample Stock Page

#### CANTEL MEDICAL

**NYSE: CML**

**Price:** 21.46 | **Change:** 0.46 | **52-wk High/Low:** 26.3/14.74

#### Performance

- **12 Mos. High/Low:** 26.3/14.74
- **52-wk High/Low:** 32.1/12.56

#### Ratings

- **Value Line:** High
- **Short-Term:** A
- **Long-Term:** B+

#### Valuation

- **Dividend Yield:** 1.09
- **P/E Ratio:** 18.4
- **Return on Equity:** 14.6%

#### Key Ratios

- **Price Stability:** 55
- **Financial Strength:** 55
- **Price Growth Persistence:** 55
- **Earnings Predictability:** 60

#### Financial Overview

- **Net Sales:** $177.4 million
- **Operating Income:** $18.5 million
- **Net Income:** $10.7 million

#### Historical Performance

- **Three-Year Average Growth:** 16.1%
- **Five-Year Average Growth:** 18.4%

#### Industry

**Industry:** Med Supp Non-Invasive

**Overview:** Can'tel Medical Corp. provides infection prevention and control products and services in the healthcare market worldwide. Its Endoscopy segment offers medical device reprocessing systems, disinfectants, detergents, and other supplies to disinfec flexible endoscopes and other approved devices; and disposable infection control products for cleaning and sterilizing various reusable components. The Water Purification and Filtration segment provides water purification equipment and services, filtration and separation products, and disinfectants. Its Healthcare Disposables segment offers single-use, infection prevention, and control products and mail-in services and in-office spore test kits for healthcare professionals. The Dialysis segment provides medical device reprocessing systems, dialysate concentrates, and other supplies for renal dialysis. Its Therapeutic Filtration segment offers hollow fiber membrane filtration and separation technologies for medical applications. Has 1177 employees.

**CEO:** Andrew A. Krakauer. Address: 150 Clove Road, 9th Floor, Little Falls, NJ 07424. Tel.: (973) 690-7220. Internet: www.cantelmedical.com

**February 24, 2012**

---

**To subscribe call 1-800-333-0046.**
Officers, directors, employees and affiliates of Value Line, Inc. ("VLI"), the parent company of Value Line Publishing LLC ("VLP") and EULAV Asset Management ("EULAV"), may hold stocks that are reviewed or recommended in this publication. EULAV also manages investment companies and other accounts that use the rankings and recommendations in this publication as part of their investment strategies. These accounts, as well as the officers, directors, employees and affiliates of VLI, may dispose of a security notwithstanding the fact that The Value Line Investment Survey (the "Survey") ranks the issuer favorably; conversely, such accounts or persons may purchase or hold a security that is poorly ranked by the Survey. Some of the investment companies managed by EULAV only hold securities with a specified minimum Timeliness Rank by the Survey and dispose of those positions when the Timeliness Rank declines or is suspended. Subscribers to the Survey and its related publications as well as some institutional customers of VLP will have access to the entire Value Line Investment Survey at 8:00 AM each Monday (or the next business day after a Monday when the New York Stock Exchange is closed). At the same time, portfolio managers for EULAV will receive reports providing Timeliness Ranking information. EULAV's portfolio managers also may have access to publicly available information that may ultimately result in or influence a change in rankings or recommendations, such as earnings releases, changes in market value or disclosure of corporate transactions. The investment companies or accounts may trade upon such information prior to a change in ranking. While the rankings in the Survey are intended to be predictive of future relative performance of an issuer's securities, the Survey is not intended to constitute a recommendation of any specific security. Any investment decision with respect to any issuer covered by the Survey should be made as part of a diversified portfolio of equity securities and in light of an investor's particular investment objectives and circumstances. Value Line, Value Line logo, The Value Line Investment Survey, Timeliness are trademarks of Value Line, Inc.